Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors

This study has been completed.
Sponsor:
Collaborator:
Thrasher Research Fund
Information provided by (Responsible Party):
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT00907244
First received: May 20, 2009
Last updated: October 26, 2012
Last verified: January 2012
  Purpose

The purpose of this study is to get information regarding the usefulness and accuracy of this new magnetic resonance imaging (MRI) technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors.


Condition
Brain Tumors

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: CHP-901:Arterial Spin Labeling Perfusion MR Imaging in Pediatric Brain Tumors

Resource links provided by NLM:


Further study details as provided by Children's Hospital of Philadelphia:

Enrollment: 13
Study Start Date: April 2008
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to get information regarding the usefulness and accuracy of this new MRI technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors. This technique can non-invasively measure the blood flow to the brain during MRI examination. Because aggressive brain tumors require new blood vessels and a high level of blood supply to support its growth, we believe the tumor blood flow measured using ASL is a reliable indicator of tumor grade. This information may be useful for doctors to make treatment decisions and to monitor patients' response to treatment.

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients between 0-18 years who are diagnosed with primary brain tumor, undergoing MRI for clinical purpose are eligible for the study.

Criteria

Inclusion Criteria:

  • Age 0-18 years
  • Primary brain tumor (newly diagnosed or recurrent) with measurable disease (at least 1cm2)

Exclusion Criteria:

  • Patients with cardiac pacemaker or ferrous metal foreign bodies
  • Patients with medical problems contradictive to receiving MRI scans.
  • Patients requiring general anesthesia or sedation for their MRI scan.
  • Patients with a history of cerebrovascular disorders (stroke, moya moya) that may alter cerebral perfusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00907244

Locations
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Children's Hospital of Philadelphia
Thrasher Research Fund
Investigators
Principal Investigator: Michael Fisher, M.D. Children's Hospital of Philadelphia
  More Information

No publications provided

Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT00907244     History of Changes
Other Study ID Numbers: CHP 901 ASL, 2008-4-5917
Study First Received: May 20, 2009
Last Updated: October 26, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Brain Neoplasms
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms

ClinicalTrials.gov processed this record on October 30, 2014